Barclays PLC Has $399,000 Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Barclays PLC grew its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 292.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 57,599 shares of the company’s stock after acquiring an additional 42,926 shares during the quarter. Barclays PLC’s holdings in Zevra Therapeutics were worth $399,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $94,000. State Street Corp lifted its stake in Zevra Therapeutics by 7.4% in the third quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares during the last quarter. Vestal Point Capital LP bought a new stake in Zevra Therapeutics in the third quarter worth approximately $3,644,000. Stonepine Capital Management LLC bought a new stake in Zevra Therapeutics in the third quarter worth approximately $4,858,000. Finally, MetLife Investment Management LLC increased its stake in shares of Zevra Therapeutics by 8.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after purchasing an additional 1,717 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Down 1.9 %

ZVRA opened at $8.59 on Friday. The business has a 50 day moving average of $8.77 and a 200-day moving average of $7.48. The stock has a market capitalization of $458.50 million, a price-to-earnings ratio of -4.36 and a beta of 1.97. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the company earned ($0.40) earnings per share. As a group, sell-side analysts anticipate that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZVRA has been the subject of a number of recent research reports. JMP Securities began coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Maxim Group raised their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Roth Mkm upped their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $21.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.